Publication | Open Access

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Lymphoid NeoplasiaMantle Cell LymphomaMedicineIbrutinib Versus TemsirolimusSurgical PathologyHematologyMalignant Blood DisorderPathologyOncologyRadiation OncologyPhase 3Health Sciences